This ExpertREACT article was originally published on 12 June 2012. Analysis and commercial assessments described reflect the state of knowledge at that date.
The B-lineage mismatch problem
Seasonal influenza B comprises two genetically distinct lineages - B/Victoria and B/Yamagata - that have co-circulated since the late 1980s with no antigenic cross-reactivity between them. Because the trivalent vaccine includes only one B lineage, vaccine mismatch against the predominant circulating B strain is common. US CDC data showed that for 5 of 10 influenza seasons between 2001 and 2010, the available trivalent vaccine provided little or no B virus protection. A recent CDC analysis estimated that widespread adoption of a quadrivalent influenza vaccine (QIV) would result in between 2,200 and 970,000 fewer cases annually in the US depending on the season - a range that itself reflects the unpredictability of B-lineage dynamics.
Children were identified as a particular beneficiary group. Serological studies had shown that children accumulate natural immunity to influenza B more slowly than to influenza A, potentially explaining an increased incidence of B illness relative to A in this age group. This added a paediatric dimension to what was primarily being positioned as an adult seasonal vaccine upgrade. The commercial precedent was clear: the switch from bivalent to trivalent formulation in 1977 - when A/H3N2 and A/H1N1 offered no cross-protection - had been a successful lifecycle transition, but it had occurred in a very different pricing environment.
Pricing strategy will determine market penetration
VacZine Analytics concluded that QIV represented the most commercially compelling lifecycle management initiative in the vaccine industry at the time of writing, but cautioned that pricing discipline would be critical. Healthcare payers and national immunisation programmes operating under austerity were unlikely to sanction significant premium pricing for a reformulation unless robust cost-effectiveness evidence was established. The risk was that QIV would follow the same path as high-dose and intradermal influenza formulations - genuinely differentiating but confined to a sub-population niche rather than replacing the standard of care across all age groups.